PHE has undertaken a number of rapid evaluations of commercial serological assays for their suitability for detecting the production of COVID-19 antibodies. Category: UncategorisedBy 16 March 2021Leave a commentPost navigationPreviousPrevious post:Research and analysis: Notifiable diseases: weekly reports for 2021NextNext post:Research and analysis: School leaver booster (Td/IPV): vaccine coverage estimates
